PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed/refractory multiple myeloma patients

被引：0
|
作者：
Ming Chen
Jinlian Zhu
Xuedong Yang
Jianxin Yao
Yuqing Liu
Qiang Liu
机构：
[1] Changshu No.2 People’s Hospital,Department of Hematology
[2] Changshu No.2 People’s Hospital,Department of Oncology
[3] Changshu No.1 People’s Hospital,Department of Hematology
来源：
European Journal of Medical Research | / 27卷
关键词：
Relapsed/refractory multiple myeloma; T cell subtype; PD-1; LAG-3;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] CLINICAL OUTCOMES ASSOCIATED WITH ANTI-CD38 RETREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REVIEW OF THE LITERATURE
    McNamara, S.
    Chorazy, J.
    Pandey, A.
    Bitetti, J.
    Boytsov, N.
    Purser, M.
    Iheanacho, I.
    VALUE IN HEALTH, 2024, 27 (06) : S31 - S31
  • [32] Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma
    Catamero, Donna
    Ray, Chloe
    Purcell, Kiah
    Leahey, Sheryl
    Esler, Elaine
    Rogers, Stephanie
    Hefner, Kayla
    O'Rourke, Lisa
    Gray, Kathleen
    Tolbert, Jaszianne
    Renaud, Thomas
    Patel, Saurabh
    Hannemann, Linda
    Shenoy, Samantha
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (05)
  • [33] A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma
    Vogl, Dan T.
    Nefedova, Yulia
    Wileyto, E. Paul
    Sembhi, Harjeet
    Strakovsky, Inna
    Nguyen, Chau
    Taneja, Rimzim
    Bondesson, Eva
    Eriksson, Helena
    Tuvesson, Helen
    BLOOD, 2020, 136
  • [34] Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs
    Gooding, Sarah
    Lau, I-Jun
    Sheikh, Mimi
    Roberts, Pamela
    Wong, Julia
    Dickens, Emmy
    Bullement, Ash
    Elvidge, Jamie
    Lee, Dawn
    Ramasamy, Karthik
    PLOS ONE, 2015, 10 (09):
  • [35] Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
    Davis, James A.
    Dima, Danai
    Ahmed, Nausheen
    DeJarnette, Shaun
    McGuirk, Joseph P.
    Khouri, Jack
    Valent, Jason
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2023, 142
  • [36] Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma
    Adegbite, Benjamin O.
    Tan, Carlyn Rose
    Shekarkhand, Tala
    Firestone, Ross S.
    Jurgens, Eric M.
    Miller, Kevin
    Lesokhin, Alexander M.
    Shah, Gunjan L.
    Korde, Neha
    Rajeeve, Sridevi
    Chung, David J.
    Landau, Heather J.
    Scordo, Michael
    Hassoun, Hani
    Maclachlan, Kylee H.
    Shah, Urvi A.
    Hultcrantz, Malin
    Hamadeh, Issam S.
    Giralt, Sergio
    Mailankody, Sham
    Usmani, Saad Z.
    Hashmi, Hamza
    BLOOD, 2024, 144 : 4735 - 4736
  • [37] Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1
    Tomasson, Michael H.
    Bahlis, Nizar J.
    Costello, Caitlin
    Raje, Noopur S.
    Levy, Moshe Y.
    Dholaria, Bhagirathbhai R.
    Solh, Melhem M.
    Damore, Michael A.
    Jiang, Sibo
    Xie, Tao
    Basu, Cynthia
    Skoura, Athanasia
    Chan, Edward Michael
    Trudel, Suzanne
    Jakubowiak, Andrzej J.
    Gasparetto, Cristina
    Chu, Michael
    Dalovisio, Andrew Peter
    Sebag, Michael
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)
    Lee, Ho Sup
    Min, Chang-Ki
    Lee, Je-Jung
    Kim, Kihyun
    Yoon, Sung-Soo
    Kim, Inho
    Bang, Soo-Mee
    Kim, Jin Seok
    Eom, Hyeon-Seok
    Yoon, Dok Hyun
    Lee, Yoojin
    Shin, Ho-Jin
    Park, Yong
    Jo, Jae-Cheol
    Lee, Won-Sik
    Do, Young Rok
    Mun, Yeung-Chul
    Lee, Mark Hong
    Kim, Hyo Jung
    Kim, Sung-Hyun
    Kim, Min Kyoung
    Lim, Sung-Nam
    Cho, Su-Hee
    Park, Seong Kyu
    Lee, Joon-ho
    Lee, Jae Hoon
    BLOOD, 2017, 130
  • [39] Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
    Richardson, PGG
    Barlogie, B
    Berenson, J
    Singhal, S
    Jagannath, S
    Irwin, D
    Rajkumar, SV
    Hideshima, T
    Xiao, H
    Esseltine, D
    Schenkein, D
    Anderson, KC
    BLOOD, 2005, 106 (09) : 2977 - 2981
  • [40] Clinical study of PD-1 inhibitor with mTOR inhibitor for relapsed and refractory brain tumors
    Chen, Zhihua
    Qiu, Yongming
    CANCER RESEARCH, 2018, 78 (13)
12345